Ethnic disparities in COVID-19 mortality and cardiovascular disease in England and Wales between 2020-2022.

Publication date: Jul 02, 2025

An increased risk of COVID-19 mortality risk among certain ethnic groups is well-reported, however data on ethnic disparities in COVID-19-related cardiovascular disease (CVD) are lacking. We estimated age-standardised incidence rates and adjusted hazard ratios for 28-day mortality and 30-day CVD by sex for individual ethnicity groups from England and Wales, using linked health and administrative data. We studied 6-level census-based ethnicity group classification, 10-level classification (only for Wales), and 19-level classification as well as any ethnicity sub-groups comprising >1000 individuals each (only for England). COVID-19 28-day mortality and 30-day CVD risk was increased in most non-White ethnic groups in England, and Asian population in Wales, between 23rd January 2020 and 1st April 2022. English data show mortality decreased during the Omicron variant’s dominance, whilst CVD risk [95% confidence interval] remained elevated for certain ethnic groups when compared to White populations (January-April 2022): by 120% [28-280%] in White and Asian men and 58% [32-90%] in Pakistan men, as compared to White British men; and by 75% [13-172%] in Bangladeshi women, 55% [19-102%] in Caribbean women, and 82% [31-153%] in Any Other Ethnic Group women, as compared to White British women. Ethnically diverse populations in the UK remained disproportionately affected by CVD throughout and beyond the COVID-19 pandemic.

Open Access PDF

Concepts Keywords
April Adult
Bangladeshi Aged
Pandemic Cardiovascular Diseases
Wales COVID-19
England
Ethnicity
Female
Health Status Disparities
Humans
Incidence
Male
Middle Aged
Risk Factors
SARS-CoV-2
Wales
White
White People
Young Adult

Semantics

Type Source Name
disease MESH COVID-19
disease MESH cardiovascular disease
drug DRUGBANK Ethionamide
disease IDO history
disease MESH infection
drug DRUGBANK Imidacloprid
disease MESH cardiovascular risk factor
disease MESH death
disease MESH stroke
disease MESH heart failure
drug DRUGBANK Coenzyme M
drug DRUGBANK Serine
drug DRUGBANK Hydroxyethyl Starch
disease MESH atrial fibrillation
disease MESH alcohol problems
disease MESH bipolar disorder
disease MESH cancer
disease MESH chronic kidney disease
disease MESH mental disorders
disease MESH schizophrenia
disease MESH dementia
disease MESH hypertension
disease MESH obesity
disease MESH osteoporosis
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease IDO country
pathway REACTOME Release
disease MESH privacy
disease IDO process
disease MESH comorbidity
disease MESH morbidities
disease MESH Social Vulnerability
drug DRUGBANK Esomeprazole
disease MESH Emergencies
disease MESH Health Status

Original Article

(Visited 2 times, 1 visits today)